FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2585335912> ?p ?o ?g. }

• W2585335912 endingPage "666" @default.
• W2585335912 startingPage "666" @default.
• W2585335912 abstract "Abstract Abstract 666 Background: The success of HCT for myelodysplastic syndrome (MDS) is hampered by regimen-related toxicity and relapse. Relapse is dependent primarily upon the patient's clonal karyotype, generally classified by IPSS into 3 groups: good, intermediate, and poor. Schanz et al. proposed a new classification that distinguishes 5 cytogenetic risk groups, very good, good, intermediate, poor and very poor, with median survivals in non-transplanted patients ranging from 61 to 6 months. Here, we determined the impact of these novel risk categories on post-HCT outcome. Methods: We analyzed results in 1042 patients with MDS (including progression to acute myeloid leukemia [tAML]) transplanted at the FHCRC; 89% of HCT were carried out since 1990. Patients were 1–75 (median 45) years old and were prepared for HCT with various high-dose or reduced/low-intensity conditioning regimens. Donors were related (54%) or unrelated (46%); the source of stem cells was marrow (52%) or G-CSF mobilized peripheral blood progenitor cells (PBPC; 48%). The association of the 5-group cytogenetic classification with HCT outcome was examined in univariate and multivariate analyses. Results: The 3-year probabilities of relapse with very good/good/intermediate/poor/very poor cytogenetics were 8%, 17%, 19%, 26% and 48%, and overall survivals were 46%, 46%, 41%, 37% and 8%, respectively. Hazard ratios (HR) from univariate analysis are shown in the table. While the impact of the 5-group cytogenetic risks “good” and “intermediate” coincided almost entirely with the IPSS cytogenetic risk groups “good” (98%) and “intermediate” (83%) respectively, the third IPSS group, “poor”, was split into the categories “intermediate” (13%), “poor” (50%) and “very poor” (36%) in the novel 5-group classification. Among patients in IPSS cytogenetic risk group “poor”, the 5-group category “very poor” had significantly worse outcome (HR=2.82 [1.78-4.46, p<.0001] for mortality; HR=3.57 [1.85-6.88, p=.0002] for relapse); outcome for the “poor” group was similar to the “intermediate” risk category in the 5-group classification (HR=1.17 [0.74-1.85, p=.49) for mortality; HR=0.99 [0.50-1.92, p=.96] for relapse). The group “very good” showed a HR of 0.494 for relapse, but with only 13 patients the difference to the “good” group was not statistically significant. Consistent with the IPSS, increasing blasts were associated with an increased risk of mortality (p=.007) and relapse (p<.0001) after adjusting for cytogenetic risk by the new 5-group classification. In addition, increasing platelet counts were associated with lower mortality (p=.0006) but not relapse (p=.85). After adjusting for cytogenetic risk and the factors listed above, increasing age was associated with a higher rate of mortality (p<.0001) but not relapse (p=.87). The risk of mortality was decreased in more recent years of HCT (p<.0001). Patients with unrelated donors had a higher rate of mortality compared to those with HLA matched-sibling donors (HR=1.34, p=.005), but also tended to have a lower relapse risk (HR=0.74, p=.08). The associations of the new 5-group karyotype categories with outcome were similar to those listed above when these other factors were not adjusted for. Conclusions: The present data confirm the profound impact of cytogenetic risk on post-HCT relapse and mortality in patients with MDS and indicate that the newly proposed classification distinguishes different risk cohorts even more clearly than the original IPSS classification. In fact, for both overall mortality and relapse the 5-group model significantly improves the previous model of only three cytogenetic risk groups (p<0.0001 for both endpoints). The data indicate, furthermore, that patient age, platelet counts, and donor type significantly impact transplant outcome. Finally, results show that outcomes with HCT in patients with MDS have improved over the years. Future trials must focus on conditioning regimens that allow to reduce non-relapse mortality in patients with low risk cytogenetics and reduce relapse incidence in patients with high-risk karyotypes. Disclosures: No relevant conflicts of interest to declare." @default.
• W2585335912 created "2017-02-10" @default.
• W2585335912 creator A5010962133 @default.
• W2585335912 creator A5023949296 @default.
• W2585335912 creator A5056405520 @default.
• W2585335912 creator A5074629157 @default.
• W2585335912 date "2011-11-18" @default.
• W2585335912 modified "2023-10-03" @default.
• W2585335912 title "Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT)" @default.
• W2585335912 doi "https://doi.org/10.1182/blood.v118.21.666.666" @default.
• W2585335912 hasPublicationYear "2011" @default.
• W2585335912 type Work @default.
• W2585335912 sameAs 2585335912 @default.
• W2585335912 citedByCount "3" @default.
• W2585335912 countsByYear W25853359122012 @default.
• W2585335912 countsByYear W25853359122015 @default.
• W2585335912 crossrefType "journal-article" @default.
• W2585335912 hasAuthorship W2585335912A5010962133 @default.
• W2585335912 hasAuthorship W2585335912A5023949296 @default.
• W2585335912 hasAuthorship W2585335912A5056405520 @default.
• W2585335912 hasAuthorship W2585335912A5074629157 @default.
• W2585335912 hasConcept C104317684 @default.
• W2585335912 hasConcept C126322002 @default.
• W2585335912 hasConcept C143998085 @default.
• W2585335912 hasConcept C144301174 @default.
• W2585335912 hasConcept C174475383 @default.
• W2585335912 hasConcept C207103383 @default.
• W2585335912 hasConcept C2776694085 @default.
• W2585335912 hasConcept C2776755627 @default.
• W2585335912 hasConcept C2777408962 @default.
• W2585335912 hasConcept C2778461978 @default.
• W2585335912 hasConcept C2779263901 @default.
• W2585335912 hasConcept C2780007613 @default.
• W2585335912 hasConcept C2780240888 @default.
• W2585335912 hasConcept C2780611847 @default.
• W2585335912 hasConcept C2780817109 @default.
• W2585335912 hasConcept C2911091166 @default.
• W2585335912 hasConcept C30481170 @default.
• W2585335912 hasConcept C38180746 @default.
• W2585335912 hasConcept C44249647 @default.
• W2585335912 hasConcept C54355233 @default.
• W2585335912 hasConcept C71924100 @default.
• W2585335912 hasConcept C86803240 @default.
• W2585335912 hasConcept C90924648 @default.
• W2585335912 hasConceptScore W2585335912C104317684 @default.
• W2585335912 hasConceptScore W2585335912C126322002 @default.
• W2585335912 hasConceptScore W2585335912C143998085 @default.
• W2585335912 hasConceptScore W2585335912C144301174 @default.
• W2585335912 hasConceptScore W2585335912C174475383 @default.
• W2585335912 hasConceptScore W2585335912C207103383 @default.
• W2585335912 hasConceptScore W2585335912C2776694085 @default.
• W2585335912 hasConceptScore W2585335912C2776755627 @default.
• W2585335912 hasConceptScore W2585335912C2777408962 @default.
• W2585335912 hasConceptScore W2585335912C2778461978 @default.
• W2585335912 hasConceptScore W2585335912C2779263901 @default.
• W2585335912 hasConceptScore W2585335912C2780007613 @default.
• W2585335912 hasConceptScore W2585335912C2780240888 @default.
• W2585335912 hasConceptScore W2585335912C2780611847 @default.
• W2585335912 hasConceptScore W2585335912C2780817109 @default.
• W2585335912 hasConceptScore W2585335912C2911091166 @default.
• W2585335912 hasConceptScore W2585335912C30481170 @default.
• W2585335912 hasConceptScore W2585335912C38180746 @default.
• W2585335912 hasConceptScore W2585335912C44249647 @default.
• W2585335912 hasConceptScore W2585335912C54355233 @default.
• W2585335912 hasConceptScore W2585335912C71924100 @default.
• W2585335912 hasConceptScore W2585335912C86803240 @default.
• W2585335912 hasConceptScore W2585335912C90924648 @default.
• W2585335912 hasIssue "21" @default.
• W2585335912 hasLocation W25853359121 @default.
• W2585335912 hasOpenAccess W2585335912 @default.
• W2585335912 hasPrimaryLocation W25853359121 @default.
• W2585335912 hasRelatedWork W187238933 @default.
• W2585335912 hasRelatedWork W2052032788 @default.
• W2585335912 hasRelatedWork W2067862448 @default.
• W2585335912 hasRelatedWork W2068538768 @default.
• W2585335912 hasRelatedWork W2092132051 @default.
• W2585335912 hasRelatedWork W2255342222 @default.
• W2585335912 hasRelatedWork W2292214042 @default.
• W2585335912 hasRelatedWork W2576480644 @default.
• W2585335912 hasRelatedWork W2585335912 @default.
• W2585335912 hasRelatedWork W3198145801 @default.
• W2585335912 hasVolume "118" @default.
• W2585335912 isParatext "false" @default.
• W2585335912 isRetracted "false" @default.
• W2585335912 magId "2585335912" @default.
• W2585335912 workType "article" @default.